ChapAte is a subcutaneously administered Chaperone, which is a medical device (PegLip), that will Chaperone the patient’s own endogenous Factor VIII for mild to moderate haemophiliacs (together about 60% of the haemophilia A population). This may provide affordable prophylaxis for these sections of the haemophiliac community who currently have to rely of treatment on demand (i.e. Accident & Emergency).

A development programme is planned to run in parallel with the LongAte (SQ) programme.